| Literature DB >> 32531427 |
Akram A Hosseini1, Ashit K Shetty2, Nikola Sprigg3, Dorothee P Auer4, Cris S Constantinescu5.
Abstract
Entities:
Mesh:
Year: 2020 PMID: 32531427 PMCID: PMC7282789 DOI: 10.1016/j.bbi.2020.06.012
Source DB: PubMed Journal: Brain Behav Immun ISSN: 0889-1591 Impact factor: 19.227
Patient data at the time of presentation to hospital and ≥48 h after the onset of altered mental status.
| Value (normal range) | Case 1 | Case 2 | ||
|---|---|---|---|---|
| at presentation | 48 h later | at presentation | 60 h later | |
| Body temperature, °C | 36.7 | 36.9 | ||
| Pulse rate, beats/minute | 86 | 90 | 91 | 82 |
| Blood pressure, mmHg | 116/74 | 142/75 | 185/93 | 147/81 |
| Oxygen saturation on air | 97% | 100% | 99% | |
| Hemoglobin, g/L (130–180) | 147 | 137 | 132 | |
| White cell count, × 109/L (4–11) | 7.12 | 9.2 | 6.36 | 9.65 |
| Neutrophil count, × 109/L (2–7) | 3.6 | 7.97 | 5.83 | 8.68 |
| Lymphocyte count, × 109/L (1–4) | 2.82 | |||
| Platelet count, × 109/L (150–450) | 313 | 232 | ||
| C-Reactive Protein, mg/L (0–10) | <5 | <5 | <5 | |
| D-Dimer, ug/L (0–500) | – | Up to | – | Up to |
| Alanine transaminase, U/L (0–35) | 15 | Up to | 12 | |
| Sodium, mmol/L (134–145) | 133 | 136 | 134 | |
| Urea, mmol/L (2–6.5) | 3.2 | 8.8 | 5.8 | 5.1 |
| Creatinine, umol/L (59–104) | 88 | 99 | 65 | 53 |
| Serum osmolality, mosmol/kg (275–295) | – | – | – | 257 |
| Urine osmolality, mosmol/kg (50–1200) | – | – | – | 664 |
| Serum glucose mmol/L (3–7.8) | 8.7 | 5.8 | 8.1 | 5.4 |
| CSF glucose, mmol/L (~60 to 80% of serum value) | – | 4.5 | – | 4.1 |
| CSF opening pressure, cmH2O | – | 18 | – | 13 |
| CSF white cell × 109/L (0) | – | 0 | – | 0 |
| CSF protein, mg/L (150–450) | – | – | 340 | |
| CSF oligoclonal bands | – | – | Not found | |
| Serum oligoclonal bands | – | – | Not found | |
| CSF PCR for SARS-CoV2 | Negative | Negative | ||
| CSF PCR for Herpes Simplex 1 and 2, Varicella zoster, enteroviruses | – | Negative | – | Negative |
| Antibodies against NMDAR, LGi1, CASPR2, GABA-B, AMPA in serum and CSF | – | Not detected | – | Not detected |
| Paraneoplastic anti-neuronal antibodies in serum and CSF | – | Not detected | – | Not detected |
| Antiphospholipid antibodies | – | Negative | – | – |
| Thrombophilia screen | – | Normal | – | – |
| Thrombin Time, seconds (14–19) | – | 16.6 | – | |
| APTT, seconds (21–29) | – | 20.8 | – | |
| Serum alpha-galactosidase A, pmol/punch/h (6.3–47) | – | 26.1 | – | – |
| 12-lead electrocardiogram | sinus rhythm | sinus rhythm | sinus rhythm | sinus rhythm |
CSF, cerebrospinal fluid; NMDAR, N-methyl-D-aspartate receptor; LGi1, leucine-rich glioma inactivated 1; CASPR2, contactin-associated protein 2; GABA-B, γ-Aminobutyric acid-B receptor; AMPA, GluR1 and GluR2 subunits of the AMPA receptor; APTT: activated partial prothrombin time.
After the onset of altered mental state.
The highest level measured between day 6 and day 8.
Paraneoplastic antibodies included anti-Hu, anti-Yo, anti-Ri, and anti-amphiphysin.
Fig. 1Case 1, MRI head 6 days after the onset of delirium: white arrows show the signal hyperintensity changes in the subcortex of the left lateral temporal lobe on T2-Weighted (A), FLAIR (B), and Diffusion Weighted Image (C), and ADC map (D).
Fig. 2Case 2, MRI head 12 days after the onset of altered mental state: white arrows show the signal hyperintensity changes in the limbic system, predominantly in the left amygdala and hippocampus on FLAIR (A), partial restricted diffusion (B, C) and T1 hypointensity on post-Gadolinium-enhanced T1-weighted image (D).